Conjugated anionic PEG-citrate G2 dendrimer with multi-epitopic HIV-1 vaccine candidate enhance the cellular immune responses in mice

References

• Abdoli A, Soleimanjahi H, Kheiri MT, Jamali A, Mazaheri V, Alitappeh AM. 2014. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice. Pathog Dis. 72:197–207.
   PubMed Web of Science ®Google Scholar
• Arabi S, Aghasadeghi MR, Memarnejadian A, Kohram F, Aghababa H, Khoramabadi N, et al. 2014. Cloning, expression and purification of a novel multi-epitopic HIV-1 vaccine candidate: a preliminary study on immunoreactivity. Vacc Res. 1:10–15.
   Google Scholar
• Ardestani MS, Fordoei AS, Abdoli A, Cohan AR, Bahramali G, Sadat SM, et al. 2015. Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity. J Mater Sci Mater Med. 26:1–8.
   Web of Science ®Google Scholar
• Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. 2008. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis. 46:1310–1314.
   PubMed Web of Science ®Google Scholar
• Davenport MP, Petravic J. 2010. CD8+ T cell control of HIV–a known unknown. PLoS Pathog. 6:e1000728.
   PubMed Web of Science ®Google Scholar
• De Rose R, Chea S, Dale CJ, Reece J, Fernandez CS, Wilson KM, et al. 2005. Subtype AE HIV-1 DNA and recombinant Fowlpox virus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine. 23:1949–1956.
   PubMed Web of Science ®Google Scholar
• Dezfuli HT, Shahbazzadeh D, Eidi A, Bagheri KP, Pakravan N, Amini S, et al. 2014. Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin. Gastroenterol Hepatol Bed Bench. 7:108–117.
   PubMedGoogle Scholar
• Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. 2005. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol. 79:14169–14178.
   PubMed Web of Science ®Google Scholar
• Faraji AH, Wipf P. 2009. Nanoparticles in cellular drug delivery. Bioorg Med Chem Bioorgan Med Chem. 17:2950–2962.
   PubMed Web of Science ®Google Scholar
• Fréchet JMJ, Tomalia DA. 2001. Dendrimers and Other Dendritic Polymers. In: Scheirs J, Ed. West Sussex: Wiley.
   Google Scholar
• Heegaard PMH, Boas U, Sorensen NS. 2009. Dendrimers for vaccine and immunostimulatory uses. A review. Bioconjug Chem Bioconjugate Chem. 21:405–418.
   PubMed Web of Science ®Google Scholar
• Kaufman DR, Barouch DH. 2009. Translational mini review series on vaccines for HIV: T lymphocyte trafficking and vaccine‐elicited mucosal immunity. Clin Exp Immunol. 157:165–173.
   PubMed Web of Science ®Google Scholar
• Kreuter J. 1995. Nanoparticles as Adjuvants for Vaccines, in Vaccine Design. New York (NY): Springer; pp. 463–472.
   Google Scholar
• Krieg AM. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 5:471–484.
   PubMed Web of Science ®Google Scholar
• Kunwar P, Hawkins N, Dinges WL, Liu Y, Gabriel EE, Swan DA, et al. 2013. Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design. PLoS One. 8:e64405.
   PubMed Web of Science ®Google Scholar
• Liu J, Gray WD, Davis ME, Luo Y. 2012. Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review. Interf Focus. 2:307–324.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xiao Y, Chen Y-H. 2003. Epitope-vaccine strategy against HIV-1: today and tomorrow. Immunobiology. 208:423–428.
   PubMed Web of Science ®Google Scholar
• Lu F, Mencia A, Bi L, Taylor A, Yao Y, HogenEsch H. 2015. Dendrimer-like alpha-d-glucan nanoparticles activate dendritic cells and are effective vaccine adjuvants. J Control Release. 204:51–59.
   PubMed Web of Science ®Google Scholar
• Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, et al. 2014. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. AIDS Res Human Retrov. 30:299–311.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliver Rev. 55:329–347.
   PubMed Web of Science ®Google Scholar
• Peng J, Wu Z, Qi X, Chen Y, Li X. 2013. Dendrimers as potential therapeutic tools in HIV inhibition. Molecules. 18:7912–7929.
   PubMed Web of Science ®Google Scholar
• Pion M, Serramia MJ, Diaz L, Bryszewska M, Gallart T, García F, et al. 2010. Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials. 31:8749–8758.
   PubMed Web of Science ®Google Scholar
• Preis I, Langer RS. 1979. A single-step immunization by sustained antigen release. J Immunol Methods. 28:193–197.
   PubMed Web of Science ®Google Scholar
• Qiu J-T, Liu B, Tian C, Pavlakis GN, Yu XF. 2000. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J Virol. 74:5997–6005.
   PubMed Web of Science ®Google Scholar
• Reynell L, Trkola A. 2012. HIV vaccines: an attainable goal? Swiss Med Wkly. 142:w13535.
   PubMed Web of Science ®Google Scholar
• Romagnani S, Prete G, Manetti R, Ravina A, Annunziato F, De Carli M, et al. 1994. Role of TH1/TH2 cytokines in HIV infection. Immunol Rev. 140:73–92.
   PubMed Web of Science ®Google Scholar
• Suhrbier A. 1997. Multi-epitope DNA vaccines. Immunol Cell Biol. 75:402–408.
   PubMed Web of Science ®Google Scholar
• Suhrbier A. 2002. Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert Rev Vaccines. 1:207–213.
   PubMedGoogle Scholar
• Sundaram R, Sun Y, Walker CM, Lemonnier FA, Jacobson S, Kaumaya PT. 2003. A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. Vaccine. 21:2767–2781.
   PubMed Web of Science ®Google Scholar
• Ullum H, Lepri AC, Bendtzen K, Victor J, Gøtzsche PC, Phillips AN, et al. 1997. Low production of interferon γ is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Res Human Retrov. 13:1039–1046.
   PubMed Web of Science ®Google Scholar
• Wang W, Guo Z, Chen Y, Liu T, Jiang L. 2006. Influence of generation 2-5 of PAMAM dendrimer on the inhibition of Tat peptide/ TAR RNA binding in HIV-1 transcription. Chem Biol Drug Des. 68:314–318.
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Loré K, Koup RA, Kedl RM, Mattapallil JJ, et al. 2005. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. P Natl Acad Sci USA. 102:15190–15194.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Lu Y, Chen YH. 2001. Epitope-vaccine as a new strategy against HIV-1 mutation. Immunol Lett. 77:3–6.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li J, Xi F, Jiang L. 2004. Polyamidoamine dendrimers inhibit binding of Tat peptide to TAR RNA. FEBS Lett. 563:241–245.
   PubMed Web of Science ®Google Scholar
• Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg AP. 2014. Nanoparticle vaccines. Vaccine. 32:327–337.
   PubMed Web of Science ®Google Scholar